Michael Weiner

Michael Weiner serves as the Founder and CEO of Abbratech and Precision Biotools, which specializes in precision-targeted therapeutic antibodies utilizing proprietary technology. Additionally, Michael is a co-founder of Encodia, a biotech firm focused on developing advanced protein analysis platforms. With a rich history in biotechnology, Michael has founded and held leadership roles in multiple companies, including AxioMx, GnuBIO, and Affomix, with a notable contribution to the invention of the first commercial Next-generation DNA sequencer at 454 Life Sciences. Michael's educational background includes a Ph.D. in Genetics from Cornell University, complemented by post-doctoral studies in Physical Chemistry from the same institution and a Bachelor of Science in Microbiology and Immunology from Penn State University.